DEF: Cartesian Therapeutics Sets 2026 Annual Meeting Date

Cartesian Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 12, 2026, to elect directors, approve executive compensation, and ratify auditor appointments.

Summary

• Cartesian Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders on Friday, June 12, 2026, at 10:00 a.m. Eastern Time.
• The meeting will be conducted virtually via live webcast, allowing stockholders to attend online and submit questions.
• Key proposals include the election of three Class I Directors (Michael Singer, M.D., Ph.D., Timothy A. Springer, Ph.D., and Patrick Zenner, M.B.A.) for terms until the 2029 Annual Meeting.
• Stockholders will also vote on a non-binding, advisory resolution to approve the compensation of named executive officers.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, will be ratified.
• The record date for determining stockholders entitled to vote is April 14, 2026, with 29,302,729 shares of Common Stock outstanding.
• The Board of Directors recommends a vote FOR all proposals.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it outlines standard corporate governance procedures and upcoming shareholder engagement, indicating ongoing operational stability.

Positives

• The company is holding its annual meeting as scheduled, indicating ongoing operational activity.
• The virtual format allows for broader stockholder participation.
• The Board of Directors is recommending approval of all proposed items, suggesting alignment with management's strategy.
• The company has a clear process for director nominations and auditor ratification, demonstrating good corporate governance practices.

Negatives

• The filing does not contain financial performance data for the current year, as it is a proxy statement for an upcoming meeting.
• The company's 2025 Annual Report on Form 10-K is referenced but not provided in full, limiting immediate access to detailed financial results.

Risks

• The staggered three-year terms for directors and the requirement for a two-thirds vote to remove directors may delay or prevent a change in management or control.
• The company's executive compensation program is heavily weighted towards variable and equity-based pay, which can be subject to stock price volatility.
• The company has experienced significant executive turnover in 2025 with the departure of Christopher Jewell, Ph.D. and Metin Kurtoglu, M.D., Ph.D.

Future Outlook

The filing primarily concerns the upcoming annual meeting and does not provide specific forward-looking financial guidance. However, the election of directors and ratification of the auditor are standard procedures for ongoing business operations.

Management Comments

• "We are very pleased that our Annual Meeting will be a completely virtual meeting of stockholders, which will be conducted via live webcast."
• "Whether or not you attend the Annual Meeting, it is important that your shares be represented and voted at the Annual Meeting. Therefore, I urge you to promptly vote and submit your proxy by phone, via the Internet, or, if you received paper copies of these materials, by signing, dating and returning the enclosed proxy card in the enclosed envelope, which requires no postage if mailed in the United States."
• "On behalf of the Board of Directors, thank you for your continued support and investment in Cartesian Therapeutics, Inc."

Industry Context

StockSavvy.ai notes that this filing is typical for a publicly traded biotechnology company preparing for its annual shareholder meeting. The focus on director elections, executive compensation, and auditor ratification are standard governance procedures. The company's lead asset, Descartes-08, is in late-stage clinical development for autoimmune diseases, a highly competitive and capital-intensive sector.

Management Changes

Corporate Governance

Related Party Transactions

• TAS, an affiliate of Dr. Timothy A. Springer, exercised warrants on March 26, 2024, for an aggregate exercise price of $2.9 million.
• In a 2023 Private Placement, the Company sold Series A Preferred Stock to Timothy A. Springer, Ph.D., TAS, and Seven One Eight Three Four Irrevocable Trust (associated with Murat Kalayoglu, M.D., Ph.D.) for $60.25 million.
• In a 2024 Private Placement, the Company sold Series B Preferred Stock to Timothy A. Springer, Ph.D., TAS, and Dr. Chafen Lu (Dr. Springer's wife).

Stakeholder Impact

• Shareholders: Will vote on director elections and executive compensation, influencing corporate governance and management alignment.
• Employees: Indirectly impacted by executive compensation decisions and corporate governance practices.
• Management: Subject to compensation review and potential changes in board composition.

Next Steps

• Stockholders to vote on the election of directors, executive compensation, and auditor ratification at the Annual Meeting on June 12, 2026.
• The company will file a Current Report on Form 8-K with the final voting results within four business days of the Annual Meeting.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial performance data or strategic updates that would warrant a change in investment recommendation. The proposals are standard governance items. Investors should refer to the company's financial reports and clinical development updates for investment decisions.

Keywords

proxy statement, annual meeting, stockholders, election of directors, executive compensation, independent auditor, corporate governance, virtual meeting, Cartesian Therapeutics, RNAC